Learn about the results of the recent study on deutetrabenazine and the ways it is helping patients with tardive dyskinesia.
Tardive dyskinesia is an irreversible movement disorder that causes involuntary movement outside of the patient's control. Three-year open-label data from the Movement Disorder Center shows TD treatment achieved sustained improvement in AIMS score and treatment response rates indicative of clinically meaningful long-term benefits.
Robert Hauser, MD, one of the authors of this study, discussed the results with Psychiatric Times.
Dr Hauser is a professor of neurology, molecular pharmacology, and physiology at the University Of South Florida Morsani College Of Medicine, in Tampa. He serves as Director of the Clinical Signature Interdisciplinary Program in Neuroscience and as Director of the USF Health Byrd Parkinson's Disease and Movement Disorders Center.